Pharmacogenomic contribution to drug response

Cancer Journal

Volumn 17, Issue 2, 2011, Pages 80-88

  Watson, Roshawn G ^a   McLeod, Howard L ^a,b  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

breast cancer; colorectal cancer; epidermal growth factor receptor; Pharmacogenomics; tamoxifen; thymidylate synthetase

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CYTOCHROME P450 2D6; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PACLITAXEL; TAMOXIFEN; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE; TRASTUZUMAB;

BREAST CANCER; CANCER RECURRENCE; COLORECTAL CANCER; DRUG INTOXICATION; GENE MUTATION; HUMAN; MOLECULARLY TARGETED THERAPY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; HUMANS; PHARMACOGENETICS;

EID: 79954562811     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182147432     Document Type: Review

References (127)

1. Yang R, Niepel M, Mitchison T, et al. Dissecting variability in responses to cancer chemotherapy through systems pharmacology. Clin Pharmacol Ther. 2010;88:34-38.
2. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracilleucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136-147. (Pubitemid 30036347)
3. Douillard J, Cunningham D, Roth A, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-1047. (Pubitemid 30162806)
4. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134:1296-1310.
5. Evans W, Relling M. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487-491.
6. Evans W, Johnson J. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet. 2001;2:9-39. (Pubitemid 35264999)
7. McLeod H, Evans W. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol. 2001;41: 101-121. (Pubitemid 32385884)
8. Evans W, McLeod H. PharmacogenomicsVdrug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-549. (Pubitemid 36159890)
9. Kalow W, Tang B, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;8:283-289. (Pubitemid 28372321)
10. Marsh S, McLeod H. Cancer pharmacogenetics. Br J Cancer. 2004; 90:8-11. (Pubitemid 38174930)
11. Watters J, McLeod H. Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta. 2003;1603:99-111. (Pubitemid 36262943)
12. Relling M, Hancock M, Rivera G, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001-2008.
13. Relling M, Hancock M, Boyett J, et al. Prognostic importance of 6- mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 1999;93:2817-2823. (Pubitemid 29200771)
14. Marsh S, McLeod H. Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer. 2001;1:175-178; discussion 9-81.
15. Kawakami K, Omura K, Kanehira E, et al. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res. 1999;19: 3249-3252. (Pubitemid 30042617)
16. Kawakami K, Salonga D, Park J, et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res. 2001;7: 4096-4101. (Pubitemid 34044633)
17. Horie N, Aiba H, Oguro K, et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct. 1995;20:191-197.
18. Villafranca E, Okruzhnov Y, Dominguez M, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol. 2001;19:1779-1786. (Pubitemid 32230880)
19. Qiu L, Tang Q, Bai J, et al. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine- based chemotherapy: evidence from 24 studies. Int J Cancer. 2008;123:2384-2389.
20. Aschele C, Debernardis D, Casazza S, et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol. 1999;17:1760-1770. (Pubitemid 29269245)
21. Popat S, Matakidou A, Houlston R. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and metaanalysis. J Clin Oncol. 2004;22:529-536. (Pubitemid 41079782)
22. Wang TL, Diaz LA, Romans K, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5- fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A. 2004;101:3089-3094. (Pubitemid 38327739)
23. Meropol N, Gold P, Diasio R, et al. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:4069-4077. (Pubitemid 46622281)
24. Aschele C, Debernardis D, Tunesi G, et al. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res. 2000;6:4797-4802. (Pubitemid 32110422)
25. Bendardaf R, Elzagheid A, Lamlum H, et al. Thymidylate synthase expression in primary colorectal tumours is correlated with its expression in metastases. Scand J Gastroenterol. 2007;42:471-476. (Pubitemid 46569405)
26. Tsuji T, Hidaka S, Sawai T, et al. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracilYbased oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res. 2003;9:3700-3704. (Pubitemid 37169238)
27. McLeod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010;28:3227-3233.
28. Tan BR, Thomas F, Myerson RJ, et al. Thymidylate synthase genotypeY directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J Clin Oncol. 2011;29:875-883.
29. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist. 2002;7(suppl 4):2-8. (Pubitemid 34977157)
30. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345. (Pubitemid 38944402)
31. Khambata-Ford S, Garrett C, Meropol N, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230-3237. (Pubitemid 47325606)
32. Karapetis C, Khambata-Ford S, Jonker D, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.
33. Tabernero J, Cervantes A, Rivera F, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol. 2010;28:1181-1189.
34. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapyrefractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304:1812-1820.
35. Roock WD, Vriendt VD, Normanno N, et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. Epub ahead of print, December 14, 2010.
36. Meta-Analysis Group In Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol. 1998;16:3537-3541.
37. Heggie G, Sommadossi J, Cross D, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47:2203-2206. (Pubitemid 17074634)
38. Wei X, McLeod H, McMurrough J, et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest. 1996;98:610-615. (Pubitemid 26349163)
39. Van Kuilenburg A, Vreken P, Abeling N, et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet. 1999;104:1-9. (Pubitemid 29134634)
40. Van Kuilenburg A, Meinsma R, Zoetekouw L, Van Gennip A. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g9a mutation. Int J Cancer. 2002;101:253-258. (Pubitemid 34970893)
41. Van Kuilenburg A, Meinsma R, Zoetekouw L, et al. High prevalence of the IVS14 + 1G9A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracilYassociated toxicity. Pharmacogenetics. 2002;12:555-558. (Pubitemid 35177085)
42. Raida M, Schwabe W, Häusler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)Yrelated toxicity compared with controls. Clin Cancer Res. 2001;7:2832-2839. (Pubitemid 32911393)
43. Salgueiro N, Veiga I, Fragoso M, et al. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-fluorouracil toxicity in Portuguese colorectal cancer patients. Genet Med. 2004;6:102-107. (Pubitemid 38523678)
44. Ahluwalia R, Freimuth R, McLeod H, et al. Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin Chem. 2003;49:1661-1664. (Pubitemid 37194222)
45. Ezzeldin H, Lee A, Mattison L, et al. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res. 2005;11:8699-8705. (Pubitemid 43005919)
46. Noguchi T, Tanimoto K, Shimokuni T, et al. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5- fluorouracil in cancer cells. Clin Cancer Res. 2004;10:7100-7107. (Pubitemid 39383062)
47. Yu JS, McLeod HL. Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 2006;12:3864. (Pubitemid 44000269)
48. Yen J, McLeod H. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer. 2007;43:1011-1016. (Pubitemid 46483039)
49. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352:1407-1412. (Pubitemid 28510873)
50. Saltz L, Cox J, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-914.
51. Rothenberg M, Kuhn J, Burris HA 3rd, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 1993;11:2194-2204.
52. Rothenberg M, Kuhn J, Schaaf L, et al. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol. 2001;12:1631-1641. (Pubitemid 34065894)
53. Cunningham D, Pyrhönen S, James R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413-1418. (Pubitemid 28510874)
54. Fuchs C, Moore M, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol. 2003;21:807-814. (Pubitemid 46606439)
55. Vanhoefer U, Harstrick A, Achterrath W, et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001;19: 1501-1518. (Pubitemid 32202559)
56. Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51:4187-4191.
57. Iyer L, King C, Whitington P, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998;101:847-854. (Pubitemid 28096082)
58. Gupta E, Lestingi T, Mick R, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994;54:3723-3725. (Pubitemid 24241187)
59. Gupta E, Mick R, Ramirez J, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol. 1997;15:1502-1510. (Pubitemid 27167386)
60. Beutler E, Gelbart T, Demina A. Racial variability in the UDPglucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A. 1998;95:8170-8174. (Pubitemid 28326085)
61. Innocenti F, Undevia S, Iyer L, et al. Genetic variants in the UDPglucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22:1382-1388. (Pubitemid 41103619)
62. Hunt S, Kronenberg F, Eckfeldt J, et al. Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. Atherosclerosis. 2001;154:747-754. (Pubitemid 32232174)
63. Lin J, Cupples L,Wilson P, et al. Evidence for a gene influencing serum bilirubin on chromosome 2q telomere: a genomewide scan in the Framingham study. Am J Hum Genet. 2003;72:1029-1034. (Pubitemid 36403322)
64. Sjögren S, Inganäs M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J ClinOncol. 1998;16:462-469. (Pubitemid 28135587)
65. Slamon D, Clark G,Wong S, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182. (Pubitemid 17231334)
66. Owens M, Horten B, Da Silva M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5:63-69. (Pubitemid 38821193)
67. Moasser M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26: 6469-6487. (Pubitemid 47530601)
68. Milanezi F, Carvalho S, Schmitt F. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn. 2008;8:417-434. (Pubitemid 351962088)
69. Sauter G, Lee J, Bartlett J, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323-1333.
70. Romond E, Perez E, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353:1673-1684. (Pubitemid 41464706)
71. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672. (Pubitemid 41464705)
72. Slamon D, Romond E, Perez E, et al. Advances in adjuvant therapy for breast cancer. Clin Adv Hematol Oncol. 2006;4(suppl 1):4-9, discussion suppl 10; quiz 2 p following suppl.
73. Joensuu H, Kellokumpu-Lehtinen P, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809-820. (Pubitemid 43290919)
74. Wolff A, Hammond M, Schwartz J, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
75. Cobleigh M, Vogel C, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648. (Pubitemid 29415219)
76. Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
77. Vogel C, Cobleigh M, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726. (Pubitemid 34111379)
78. Mass R, Press M, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005;6:240-246. (Pubitemid 47050800)
79. Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat. 2005;93:3-11. (Pubitemid 41355986)
80. Press M, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11:6598-6607. (Pubitemid 41339000)
81. Yaziji H, Goldstein L, Barry T, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291:1972-1977. (Pubitemid 38544278)
82. Dowsett M, Bartlett J, Ellis I, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol. 2003; 199:418-423. (Pubitemid 36411217)
83. Lal P, Salazar P, Hudis C, et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dualcolor and single-color scoring. Am J Clin Pathol. 2004;121:631-636. (Pubitemid 38533994)
84. Di Leo A, Gomez H, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008; 26:5544-5552.
85. Press M, Finn R, Cameron D, et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res. 2008;14:7861-7870.
86. Schmitt F. HER2+ breast cancer: how to evaluate? Adv Ther. 2009; 26(suppl 1):S1-S8.
87. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testingVNational Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94:852-854. (Pubitemid 34705057)
88. Pandolfi P. Breast cancerVloss of PTEN predicts resistance to treatment. N Engl J Med. 2004;351:2337-2338. (Pubitemid 39552753)
89. Nagata Y, Lan K, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117-127. (Pubitemid 39485684)
90. Berns K, Horlings H, Hennessy B, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395-402. (Pubitemid 47539306)
91. Spector N, Blackwell K. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2Ypositive breast cancer. J Clin Oncol. 2009;27:5838-5847.
92. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124-1130.
93. Geyer C, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355: 2733-2743. (Pubitemid 46021510)
94. Albain K, Paik S, van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast. 2009;18(suppl 3):S141-S145.
95. Dobbe E, Gurney K, Kiekow S, et al. Gene-expression assays: new tools to individualize treatment of early-stage breast cancer. Am J Health Syst Pharm. 2008;65:23-28.
96. Marchionni L, Wilson R, Wolff A, et al. Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med. 2008;148:358-369. (Pubitemid 351665467)
97. Ross J, Hatzis C, Symmans W, et al. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008;13:477-493. (Pubitemid 351872866)
98. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351:2817-2826. (Pubitemid 40051905)
99. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726-3734. (Pubitemid 46622311)
100. Fan C, Oh D, Wessels L, et al. Concordance among gene-expressionY based predictors for breast cancer. N Engl J Med. 2006;355:560-569. (Pubitemid 44200649)
101. Habel L, Shak S, Jacobs M, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph nodeY negative patients. Breast Cancer Res. 2006;8:R25.
102. Chang J, Makris A, Gutierrez M, et al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat. 2008;108:233-240. (Pubitemid 351311356)
103. Knauer M, Mook S, Rutgers E, et al. The predictive value of the 70- gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat. 2010;120:655-661.
104. NCCN Practice Guidelines in Oncology Invasive Breast Cancer. In: www.NCCN.org, v.2.2010.
105. Cole M, Jones C, Todd I. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971; 25:270-275
106. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet. 1983;1:257-261.
107. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479-484 (Pubitemid 19062522)
108. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
109. Goetz M, Kamal A, Ames M. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther. 2008;83:160-166.
110. Stein R, Dowsett M, Hedley A, et al. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer. 1990;62:679-683. (Pubitemid 20340591)
111. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97:30-39.
112. Stearns V, Johnson M, Rae J, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95: 1758-1764. (Pubitemid 38008898)
113. Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006;80:61-74. (Pubitemid 43946844)
114. Brauch H, Jordan V. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach? Eur J Cancer. 2009;45:2274-2283.
115. Griese E, Zanger U, Brudermanns U, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 1998;8:15-26. (Pubitemid 28097597)
116. Raimundo S, Toscano C, Klein K, et al. A novel intronic mutation, 2988G9A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther. 2004; 76:128-138. (Pubitemid 39013403)
117. Sachse C, Brockmö ller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284-295. (Pubitemid 27058401)
118. Sistonen J, Sajantila A, Lao O, et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007;17:93-101.
119. Goetz M, Rae J, Suman V, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23:9312-9318.
120. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25:5187-5193. (Pubitemid 350232249)
121. Goetz M, Knox S, Suman V, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101:113-121. (Pubitemid 47555336)
122. Xu Y, Sun Y, Yao L, et al. Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol. 2008;19:1423-1429.
123. Kiyotani K, Mushiroda T, Sasa M, et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 2008;99:995-999. (Pubitemid 351997603)
124. Nowell S, Ahn J, Rae J, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat. 2005;91: 249-258. (Pubitemid 40903087)
125. Wegman P, Vainikka L, Stål O, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 2005;7:R284YR290.
126. Wegman P, Elingarami S, Carstensen J, et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 2007;9:R7.
127. Hertz D, McLeod H, Hoskins J. Pharmacogenetics of breast cancer therapies. Breast. 2009;18(suppl 3):S59-S63.